Milestone Pharmaceuticals’ (MIST) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Milestone Pharmaceuticals (NASDAQ:MIST) in a report issued on Monday morning, Benzinga reports. They currently have a $25.00 target price on the stock.

Separately, Rodman & Renshaw began coverage on shares of Milestone Pharmaceuticals in a research note on Thursday, August 22nd. They set a “buy” rating and a $9.00 price target for the company.

Milestone Pharmaceuticals Stock Performance

Milestone Pharmaceuticals stock opened at $1.46 on Monday. The company has a 50 day moving average price of $1.47 and a 200-day moving average price of $1.53. The company has a debt-to-equity ratio of 1.61, a quick ratio of 19.13 and a current ratio of 19.13. Milestone Pharmaceuticals has a fifty-two week low of $1.12 and a fifty-two week high of $3.52. The company has a market capitalization of $77.76 million, a PE ratio of -1.17 and a beta of 1.72.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.05. As a group, equities analysts forecast that Milestone Pharmaceuticals will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. Valeo Financial Advisors LLC raised its stake in Milestone Pharmaceuticals by 100.0% in the third quarter. Valeo Financial Advisors LLC now owns 20,000 shares of the company’s stock worth $30,000 after buying an additional 10,000 shares in the last quarter. Lion Point Capital LP raised its stake in Milestone Pharmaceuticals by 1.7% in the second quarter. Lion Point Capital LP now owns 2,340,207 shares of the company’s stock worth $3,089,000 after buying an additional 40,000 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in Milestone Pharmaceuticals by 177.0% in the first quarter. BNP Paribas Financial Markets now owns 16,900 shares of the company’s stock worth $30,000 after purchasing an additional 10,800 shares during the last quarter. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.